Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine

Haematologica

Volumn 98, Issue 8, 2013, Pages

  Xicoy, Blanca ^a   Miralles, Pilar ^b   Morgades, Mireia ^a   Rubio, Rafael ^c   Valencia, María Eulalia ^d   Ribera, Josep Maria ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV related; Hodgkin's lymphoma; Long term follow up; Opportunistic infections; Second cancers

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

CANCER RECURRENCE; CD4 LYMPHOCYTE COUNT; EVENT FREE SURVIVAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; METASTASIS; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; VIRUS LOAD; HIV-RELATED; LONG-TERM FOLLOW UP; MORTALITY; SECOND CANCER; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

HIV-RELATED; HODGKIN'S LYMPHOMA; LONG-TERM FOLLOW UP; OPPORTUNISTIC INFECTIONS; SECOND CANCERS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FOLLOW-UP STUDIES; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84880994938     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.079921     Document Type: Letter

References (11)

1. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica. 2007;92(2):191-8.
2. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100(6):1984-8.
3. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, et al. Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. J Clin Oncol. 2012;30(33):4117-23.
4. Spina M, Rossi G, Antinori A, Fasan M, Schiantarelli C, Nigra E, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol. 2008;152:227a (Abstract).
5. Ribera JM, Navarro JT, Oriol A, López-Guillermo A, Sureda A, Abella E, et al. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS. 2002;16(14):1973-6.
6. Ribera JM, Navarro JT. Human immunodeficiency virus-related non-Hodgkin's lymphoma. Haematologica. 2008;93(8):1129-32.
7. Hoffmann C, Chow KU, Wolf E, Faetken heuer G, Stellbrink HJ, van Lunzen J, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004;125(4):455-62.
8. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIVinfected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23(13):41-50.
9. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Int. Med. 2008;148(10):728-36.
10. Ribera JM, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, et al. Long-term follow-up of patients with HIV-related diffuse arge B-cell lymphomas treated in a phase II study with rituximab and CHOP. Br J Haematol. 2012;157(5):637-9.
11. Gaidano G, Carbone A, Dalla-Favera R. Pahogenesis of AIDS-related lymphomas. Am J Pathol. 1998;152(3):623-30.